ASX - By Stock
|
MSB |
Re:
CHF - MSB's Dark Horse with Multi-billion dollar potential
|
|
Tappa68
|
516 |
155K |
13 |
16/07/22 |
16/07/22 |
ASX - By Stock
|
516
|
155K
|
13
|
|
ASX - By Stock
|
MSB |
Re:
Novartis walked due to "sub par data".
|
|
Tappa68
|
143 |
41K |
7 |
17/12/21 |
17/12/21 |
ASX - By Stock
|
143
|
41K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDAs OTAT Agrees to Primary Endpoint for Back Pain
|
|
Tappa68
|
408 |
123K |
1 |
16/12/21 |
16/12/21 |
ASX - By Stock
|
408
|
123K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Novartis and Mesoblast Remestemcel-L Collaboration
|
|
Tappa68
|
811 |
332K |
0 |
15/12/21 |
15/12/21 |
ASX - By Stock
|
811
|
332K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on Novartis Agreement
|
|
Tappa68
|
850 |
250K |
1 |
14/12/21 |
14/12/21 |
ASX - By Stock
|
850
|
250K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Growing doubt on COVID-19 Application
|
|
Tappa68
|
4.7K |
1.1M |
3 |
07/12/21 |
07/12/21 |
ASX - By Stock
|
4.7K
|
1.1M
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Novartis countdown
|
|
Tappa68
|
373 |
112K |
7 |
03/12/21 |
03/12/21 |
ASX - By Stock
|
373
|
112K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
15 Days until doubt is removed
|
|
Tappa68
|
953 |
289K |
0 |
28/11/21 |
28/11/21 |
ASX - By Stock
|
953
|
289K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Growing doubt on COVID-19 Application
|
|
Tappa68
|
4.7K |
1.1M |
3 |
09/11/21 |
09/11/21 |
ASX - By Stock
|
4.7K
|
1.1M
|
3
|
|
ASX - By Stock
|
MSB |
Re:
the shorts will bail with margin calling and announcements due
|
|
Tappa68
|
482 |
120K |
1 |
25/10/21 |
25/10/21 |
ASX - By Stock
|
482
|
120K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
the shorts will bail with margin calling and announcements due
|
|
Tappa68
|
482 |
120K |
0 |
25/10/21 |
25/10/21 |
ASX - By Stock
|
482
|
120K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Where is Novartis?
|
|
Tappa68
|
1.5K |
412K |
2 |
21/10/21 |
21/10/21 |
ASX - By Stock
|
1.5K
|
412K
|
2
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Tappa68
|
10K |
3.0M |
2 |
21/09/21 |
21/09/21 |
ASX - By Stock
|
10K
|
3.0M
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Tappa68
|
17K |
6.6M |
3 |
19/09/21 |
19/09/21 |
ASX - By Stock
|
17K
|
6.6M
|
3
|
|
ASX - By Stock
|
MSB |
Re:
NEJM CHF Imminent
|
|
Tappa68
|
270 |
80K |
2 |
17/09/21 |
17/09/21 |
ASX - By Stock
|
270
|
80K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Growing doubt on COVID-19 Application
|
|
Tappa68
|
4.7K |
1.1M |
1 |
11/09/21 |
11/09/21 |
ASX - By Stock
|
4.7K
|
1.1M
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Growing doubt on COVID-19 Application
|
|
Tappa68
|
4.7K |
1.1M |
0 |
11/09/21 |
11/09/21 |
ASX - By Stock
|
4.7K
|
1.1M
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Growing doubt on COVID-19 Application
|
|
Tappa68
|
4.7K |
1.1M |
0 |
11/09/21 |
11/09/21 |
ASX - By Stock
|
4.7K
|
1.1M
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Growing doubt on COVID-19 Application
|
|
Tappa68
|
4.7K |
1.1M |
1 |
09/09/21 |
09/09/21 |
ASX - By Stock
|
4.7K
|
1.1M
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Moderated
|
|
Tappa68
|
1.5K |
499K |
0 |
09/09/21 |
09/09/21 |
ASX - By Stock
|
1.5K
|
499K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Moderated
|
|
Tappa68
|
1.5K |
499K |
0 |
09/09/21 |
09/09/21 |
ASX - By Stock
|
1.5K
|
499K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Near term catalyst discussion
|
|
Tappa68
|
51 |
12K |
2 |
02/09/21 |
02/09/21 |
ASX - By Stock
|
51
|
12K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Give Tommy a Headline!
|
|
Tappa68
|
77 |
17K |
0 |
31/08/21 |
31/08/21 |
ASX - By Stock
|
77
|
17K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Growing doubt on COVID-19 Application
|
|
Tappa68
|
4.7K |
1.1M |
15 |
28/08/21 |
28/08/21 |
ASX - By Stock
|
4.7K
|
1.1M
|
15
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Tappa68
|
10K |
3.0M |
1 |
26/08/21 |
26/08/21 |
ASX - By Stock
|
10K
|
3.0M
|
1
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Tappa68
|
10K |
3.0M |
1 |
26/08/21 |
26/08/21 |
ASX - By Stock
|
10K
|
3.0M
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Moderated
|
|
Tappa68
|
1.5K |
499K |
2 |
25/07/21 |
25/07/21 |
ASX - By Stock
|
1.5K
|
499K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Risk management
|
|
Tappa68
|
95 |
23K |
0 |
29/05/21 |
29/05/21 |
ASX - By Stock
|
95
|
23K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Tappa68
|
9.5K |
2.8M |
0 |
27/05/21 |
27/05/21 |
ASX - By Stock
|
9.5K
|
2.8M
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast in Freefall
|
|
Tappa68
|
982 |
282K |
0 |
30/04/21 |
30/04/21 |
ASX - By Stock
|
982
|
282K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Tappa68
|
17K |
6.6M |
1 |
13/04/21 |
13/04/21 |
ASX - By Stock
|
17K
|
6.6M
|
1
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Tappa68
|
10K |
3.0M |
4 |
09/04/21 |
09/04/21 |
ASX - By Stock
|
10K
|
3.0M
|
4
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Tappa68
|
10K |
3.0M |
0 |
02/04/21 |
02/04/21 |
ASX - By Stock
|
10K
|
3.0M
|
0
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Tappa68
|
10K |
3.0M |
1 |
28/03/21 |
28/03/21 |
ASX - By Stock
|
10K
|
3.0M
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Deadline for Novartis
|
|
Tappa68
|
429 |
129K |
1 |
26/03/21 |
26/03/21 |
ASX - By Stock
|
429
|
129K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Deadline for Novartis
|
|
Tappa68
|
429 |
129K |
5 |
25/03/21 |
25/03/21 |
ASX - By Stock
|
429
|
129K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Tappa68
|
17K |
6.6M |
1 |
22/03/21 |
22/03/21 |
ASX - By Stock
|
17K
|
6.6M
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Calling All MSB shareholders longs, Long institutions.
|
|
Tappa68
|
12 |
4.2K |
4 |
21/03/21 |
21/03/21 |
ASX - By Stock
|
12
|
4.2K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Questions for MSB Management:
|
|
Tappa68
|
106 |
27K |
5 |
17/03/21 |
17/03/21 |
ASX - By Stock
|
106
|
27K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
The investment case FOR Mesoblast
|
|
Tappa68
|
422 |
143K |
1 |
11/03/21 |
11/03/21 |
ASX - By Stock
|
422
|
143K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
MSB Holders Only
|
|
Tappa68
|
518 |
145K |
1 |
10/03/21 |
10/03/21 |
ASX - By Stock
|
518
|
145K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Half Year Report and Accounts (including Appendix 4D)
|
|
Tappa68
|
297 |
100K |
1 |
27/02/21 |
27/02/21 |
ASX - By Stock
|
297
|
100K
|
1
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Tappa68
|
10K |
3.0M |
0 |
24/02/21 |
24/02/21 |
ASX - By Stock
|
10K
|
3.0M
|
0
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Tappa68
|
10K |
3.0M |
6 |
23/02/21 |
23/02/21 |
ASX - By Stock
|
10K
|
3.0M
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Novartis - Heart Failure - Primary Endpoints
|
|
Tappa68
|
100 |
27K |
3 |
19/02/21 |
19/02/21 |
ASX - By Stock
|
100
|
27K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Remestemcel-L for COVID-19 MIS-C published in Pediatrics
|
|
Tappa68
|
423 |
124K |
6 |
17/02/21 |
17/02/21 |
ASX - By Stock
|
423
|
124K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
Tappa68
|
5.1K |
2.5M |
3 |
13/02/21 |
13/02/21 |
ASX - By Stock
|
5.1K
|
2.5M
|
3
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Tappa68
|
10K |
3.0M |
3 |
10/02/21 |
10/02/21 |
ASX - By Stock
|
10K
|
3.0M
|
3
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Tappa68
|
10K |
3.0M |
2 |
07/02/21 |
07/02/21 |
ASX - By Stock
|
10K
|
3.0M
|
2
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Tappa68
|
10K |
3.0M |
3 |
07/02/21 |
07/02/21 |
ASX - By Stock
|
10K
|
3.0M
|
3
|
|